#LCSM

#LCSM Chat Topic 4-Feb-2021: “#WCLC20 from the comfort of your own home”

Well, we finally moved on to 2021, only to be thrust seemingly backward to #WCLC20!  The incredible content from #WCLC20 was certainly worth the wait.  Although we didn’t get to experience the meeting live together in Singapore, a new virtual platform brought it all to us in the comfort of our own homes. Several topics discussed at #WCLC20 stood out and deserve a deeper dive within the #LCSM community.

There was a great deal of buzz about the TALENT study from Taiwan which looked at lung cancer screening in never or light smokers.  Many in the lung cancer community, particularly many of those patients with actionable molecular alterations, have long been frustrated by the lack of opportunity for screening in never smokers.  Perhaps TALENT and some other work presented at #WCLC20 may get us closer to broader screening criteria.

Another topic which continues to generate excitement is using targeted therapy to treat lung cancer patients whose tumors harbor KRAS mutations.  We learned more about some of these drugs at #WCLC20 and are beginning to understand how they fit into the treatment landscape.

We also saw progress reported in mesothelioma and small cell lung cancer, two subtypes of lung cancer for which we have fewer therapeutic options.  The CONFIRM trial in mesothelioma and several presentations on small cell lung cancer were highlighted, getting us closer to personalized, biomarker driven treatments in these challenging diseases.

Strong patient voices were also represented at #WCLC20.  This included input into what clinical trials should look like in 2020 and beyond.  There was great discussion on the need to make clinical trials more patient centric, a topic which is undoubtedly important to the #lcsm community.

Finally, there was a great session on “Affordable and Accessible Lung Cancer Care” and a press conference focused on overcoming disparities of care.  Clearly, these are critical issues for our community and for the world moving forward.  We have to ensure that all patients, no matter their race, location, or socioeconomic status are able to access and take advantage of the incredible advances we have made in lung cancer screening, diagnosis, treatment, and care.

With those highlights in mind, thoracic surgeon Dr. Brendon Stiles (@BrendonStilesMD) is excited to moderate this week’s #LCSM Chat.   Please join us on Thursday, February 4th, at 8 pm Eastern Time (5 pm Pacific) to address the following topics:

  • T1.  Can and should we screen for lung cancer in never smokers?
  • T2.  How will KRAS inhibitors fit into the treatment of lung cancer?
  • T3.  What is new in mesothelioma and small cell lung cancer?
  • T4.  How can we make clinical trials better and more patient centric?
  • T5.  How can we improve access to and affordability of lung cancer care?

Please join us, and bring your experiences and wisdom!  Remember to include #LCSM in ALL your tweets so the other chat participants can see them. You can read a primer on participating in the chat here.

#LCSM Chat Topic 01/07/2021: What are your predictions for the Rx of #LungCancer in 2021?

As we bring in the New Year, our 8th #LCSM year, the #LCSM Chat on January 7, 2021, at 8 pm Eastern (5 pm Pacific) will be the Nostradamus chat (or Carnac the Magnificent for our colleagues of a certain age). We ask what are your bold predictions for innovations, policy changes, advocacy strategies and anything else in the prevention, detection, treatment of lung cancer and support of the associated community? 

Our moderator, your friendly neighborhood thoracic surgeon, David Tom Cooke (@DavidCookeMD) will lead the discussion with these questions, as well as some on the fly follow up questions:

  • T1: Healthcare has made a ton of changes during the #COVID19Pandemic.  Which #COVID19 changes have been best in the treatment of #LungCancer? Which will stick around in 2021 and after? #LCSM
  • T2: What developments and advances will we see in 2021 in regard to #LungCancerScreening? #LCSM
  • T3: What #ClinicalTrials results/prelim data are you looking forward to in 2021? #LCSM
  • T4: What will the dissemination of new #lungcancer data look like in 2021?  Back to in person meetings? Role of #SoMe?  Data science innovations? #SciComm #LCSM
  • T5: What new treatments do you see emerging in 2021?  Systemic (#MedOnc), local (#surgery #tssmn, #RadOnc), #PatientCentered, psychosocial, intersection of all the above? #LCSM
  • T6: What strategies, new methods, successes do you anticipate in #lungcancer advocacy in 2021? #LCSM
  • T7: What adjustments/evolutions do you see for the #LCSM movement in 2021? #LCSM

Please join us, and bring your experiences and wisdom!  Remember to include #LCSM in ALL your tweets so the other chat participants can see them. You can read a primer on participating in the chat here.

#LCSM Chat Topic 12/03/2020: 2020–Wild Year for #LungCancer

The #LCSM Chat on December 3, 2020, at 8 pm Eastern (5 pm Pacific) will review Lung Cancer Awareness Month activities, highlight ways 2020 impacted the lung cancer community, and share our hopes for 2021.

 Our moderator Janet Freeman-Daily (@JFreemanDaily) will lead the discussion with these questions:

  • T1: How did you acknowledge Lung Cancer Awareness Month (#LCAM) this November?
  • T2: What 2020 research findings were most important to you?
  • T3: What new treatments were approved for lung cancer in 2020?
  • T4: How else did lung cancer care change in 2020 (cough*#COVID19*cough)?
  • T5: What are your hopes for the lung cancer community in 2021?

Please join us, and bring your experiences and wisdom!  Remember to include #LCSM in ALL your tweets so the other chat participants can see them. You can read a primer on participating in the chat here.

%d bloggers like this: